Corcept Therapeutics Incorporated (CORT) Reports 105-Month Response in One Cancer Patient

Corcept Therapeutics (CORT) reported a single patient with metastatic vulvar cancer responded to relacorilant plus nab-paclitaxel for over 105 months. The patient remains in treatment with stable disease, but the company cautioned this is an early case and may not reflect broader outcomes.

Original reporting
Published Nov 16, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Corcept Therapeutics Incorporated (CORT) Reports 105-Month Response in One Cancer Patient — source image
Decision brief

The 30-second read

$CORTBullishLow
01

Why it matters

The unusually long response could attract investor attention and potential partnership interest, but clinical significance remains uncertain.

02

Market read

A rare, long‑term response in a heavily pretreated patient may boost speculative interest in CORT.

03

What to watch

Regulatory pathway and need for larger trials could delay commercial impact.

Relevance 8/10Novelty 8/10Timing: immediate today

Background

Corcept Therapeutics (CORT) focuses on glucocorticoid‑receptor antagonists; relacorilant is its lead candidate.

Company-level read

Ticker impact

$CORTBullishMedium confidence
Context

Corcept disclosed a 105‑month response in a single metastatic vulvar cancer patient to relacorilant plus nab‑paclitaxel.

Expected impact

potential upside as investors weigh the unprecedented response signal

Evidence & confidence

The result is novel and positive, yet limited to one patient, so market reaction may be modest.

Market effects

may raise interest in glucocorticoid‑receptor antagonists and niche oncology pipelines

limited to US biotech investors

minimal beyond specialty oncology niche

Counterpoint

Skeptics may view the single‑patient data as anecdotal and not price‑moving.

Key entities

  • Corcept Therapeutics Incorporated

    Biopharma developing relacorilant.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.

$CORTHighAI 8/10

Corcept’s (NASDAQ:CORT) Q3 2026: beats on revenue

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $340.5M, up 64% YoY and 1.9% above estimates. EPS of $1.01 beat estimates by 27.2%. The company reconfirmed its full-year revenue guidance of $1.15B. Operating margin improved to 33.7% YoY. CEO highlights growth in endocrinology and ovarian cancer treatments.